AbstractAims To investigate the efficacy of the Neuropen, a new clinical device that assesses both pain and pressure perception, to evaluate peripheral nerve function in diabetic patients compared with standard clinical testing methods.Methods Peripheral nerve function was assessed in 124 diabetic patients attending a multidisciplinary diabetes clinic, using (i) the modified Neuropathy Disability Score (NDS), derived from assessment of vibration, pinprick (pain), temperature sensation plus ankle reflexes, and (ii) vibration perception threshold (VPT) measured at the hallux. Patients were stratified into various neuropathic groups according to their NDS score. In addition, nerve function was assessed using the Neuropen, a device combining a 10‐g monofilament and a weighted NeurotipTM. Inability to feel sensation on either or both feet for each test of the Neuropen (i.e. the monofilament or the NeurotipTM) was defined as an abnormal response.Results The sensitivity of the Neuropen to detect neuropathy compared with the NDS (score ≥ 6/10) was high using either an abnormal monofilament response (87.8%), an abnormal NeurotipTM response (91.8%) or a combination of the two (82.0%). Neurop
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً